

Improving Health Outcomes and Economics with Innovative Diagnostic Testing



CAUTIONARY NOTES

You Must Read this Before Continuing

The information contained in this corporate presentation ("Presentation") of SQI Diagnostics Inc. ("SQI", the "Company", "we", "us", or "our") has been prepared for informational purposes regarding the business of SQI only and should be read together with the more detailed information and financial data and statements available on the Company's profile at www.sedar.com. No part of this Presentation should form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. The delivery of this Presentation, at any time, does not and will not imply that the information contained in this Presentation is correct or complete as of any time subsequent to the date set forth on the cover page of this Presentation or the date at which such information is expressed to be stated, as applicable. Under no circumstances may the contents of this Presentation and disclaims and excludes any and all for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this Presentation, its accuracy, completeness or by reason of reliance by any person on any of it.

FORWARD-LOOKING INFORMATION. This Presentation contains "forward-looking information" within the meaning of applicable Canadian securities legislation and "forward-looking statements" withing the meaning of applicable United States securities legislation (together, **"forward-looking statements"**) concerning the business, operations and financial performance and condition of SQI. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this Presentation. Generally, any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.

Forward-looking statements are based on the opinions and estimates of management of SQI as of the date such statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of SQI to be materially different from those expressed or implied by such forward-looking statements, including those and other risk factors set out in the Company's public disclosure filings available on the Company's profile at www.sedar.com. If any risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking statements prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking statements. There may be other risk factors not presently known that are believed not to be material that could also cause actual results or future events to differ materially from those expressed in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results and will not necessarily be accurate indications of whether or not the times at or by which such performance or results will be achieved. Except as expressly required by applicable Canadian securities law, SQI assumes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements in this Presentation are qualified by these cautionary statements.

CAUTIONARY NOTES CONTINUED

MARKET AND INDUSTRY DATA - This Presentation includes market and industry data and forecasts that were obtained from third-party sources, industry publications and publicly available information. Third-party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there can be no assurance as to the accuracy or completeness of included information. Although management of SQI believes it to be reliable, it has not independently verified any of the data from third-party sources referred to in this Presentation or analyzed or verified the underlying studies or surveys relied upon or referred to by such sources, or ascertained the underlying economic assumptions relied upon by such sources. The Company makes no representations or warranties as to the accuracy of such information and accept no liability therefor. All product and company names are trademarks[™] or registered[®] trademarks of their respective holders.

FUTURE ORIENTED FINANCIAL INFORMATION - To the extent any forward-looking statements in this Presentation constitute "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate management's future expectations for the business and products of SQI, including the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to numerous important factors, risks, uncertainties and assumptions relating to the price, market demand, competitive pressures, and other factors. Our actual financial position and results of operations may differ materially from management's current expectations and, as a result, our revenue and profitability may differ materially from any revenue or profitability profiles provided in this Presentation. Such information is presented for illustrative purposes only and may not be an indication of our actual financial position or results of operations.

In addition, any statements relating to financial measures such as potential annual sales figures or size of prospective markets, specifically, are based on a number of uncertainties, including, but not limited to: the development and viability the each of the SQI's diagnostic tests and test kits **("Tests"**), the suitability of such Tests for advanced clinical testing, including human trials, the content and timing of decisions made by the FDA and/or Health Canada relating to the use and commercialization of such Tests, the timing and costs involved in establishing the commercialization of the Tests, future market demand for, and acceptance of, the Tests, the impact that the ongoing COVID-19 pandemic may have on the SQI's business, including the expected development, manufacturing, regulatory and commercialization timelines relating to the referenced Tests.



Precision Medicine & Diagnostics for Respiratory Health

We are leaders in the science of lung health.


We develop and manufacture a portfolio of respiratory health and precision medicine tests that run on SQI's full range of Dx systems.

Our multiplexed tests simplify and improve :

- Donor organ transplant informatics;
- Rapid Acute Lung Injury testing;
- COVID-19 diagnoses and antibody monitoring

Our mission is to reduce waiting lists, make more donor organs available to recipients, improve respiratory health and reduce healthcare costs by over \$1 billion

Corporate Highlights



Experienced Management Team





Dr. Eric Brouwer

CSO of Trinity Biotech plc

CEO of Fiomi Biotech

Director of Assay R&D at Abbott Diagnostics

Senior Scientist at the pointof-care diagnostic innovator i-STAT (acquired by Abbott Diagnostics)



Morlan Reddock

CFO

Director of Finance for Greater Toronto Airport Authority

VP Finance for Ronnex Distribution

Director of Finance Treasury and Investor Relations for SiriusXM Canada.



Tim McGough


20 years experience cardiovascular and hemodynamic biotech commercialization

Sr VP Caretaker Medical w/lead Investor Philips Healthcare Sr VP Medica Corp

Sr. Director ZOLL Medical Acquired for \$2.2B by Asahi-Kasei

Lung Health Continuum of Care

SQI provides precision medicine tests for lung health from triage through post-transplant monitoring





Note: 1 : Currently Point of Care ("POC") ; 2 Home collection

Regulatory Status

RALI-Dx™ RALI- <i>fast</i>	 RALI Dx Health Canada Interim Order received in October 2022 RALI-fast Developing clinical study to support regulatory submission
TORdx™ Lung	 TOR<i>dx</i> LUNG FDA pre-submission dialogue in progress
Breathe	 Fungal (Aspergillus) Infection European clinical study ongoing to support regulatory submission Acute Cellular Rejection Initiating proof-of-principle clinical study
SQI Proprietary Products	NYSDOH approval - CLIA laboratory EXACT COVID-19 Antibody CELIAC Home Test Rheumatoid Arthritis Home Test



Path to Commercialization

RALI-Dx[™]/RALI-fast

RALI-Dx

- Health Canada Interim Order approved in October 2022
- Regulatory approval in the US expected in 2024
- Two Sites in Toronto

RALI-fast

- Product development completed
- Regulatory approval is required
- Partner for distribution is required (in discussion with multiple parties)



Breathe

Organ Rejection

- There exists technology risk on rejection
- This product is disruptive, is in early stage of development and requires education and adoption

Fungal (Aspergillus) Infection

- Complete pivotal clinical studies for regulatory filings
- Leading KOLs to endorse adoption



TOR*dx*[™] LUNG

- Requires regulatory approval
- FDA Pre-submission meeting targeted for 1Q23
- Educate leading Lung EVLP hospitals through sales teams
- Leveraging SQI's clinical studies to expand into key centers in the USA

COVID-19 Tests

Distribution Business

 Demand for COVID-19 Testing Products exists and the Company is actively distributing these products in Canada

EXACT COVID19 Antibody

 EXACT COVID19 Antibody Testing Products to be launched through virtual health channel partner mid-Feb 2023

Total Addressable Market (USA)

SQI's management estimates that the total addressable market for its breakthrough proprietary products is approximately USD 2 billion


		Focus Areas	US Dollars		
RALI-Dx RALI- <i>fast</i>	Respiratory Distress	Intensive Care Unit ("ICU") Emergency Room ("ER")	>\$1 Billion		
TOR <i>dx</i> ORGAN	Transplant	Lung Kidney Liver	>\$400 Million		
BREATHE	Non-invasive Post Transplant Monitoring	Aspergillus Infection Rejection	>\$200 Million		



The UNMET Need is assessing the health and quality of the donor lung with a quantitative measure to help decide if it is suitable for transplantation

- > 15,000 donor lungs available in North America yearly
 only about 3,000 transplanted (20%)¹
- > There is no quantitative test to detect inflammation or health of organ

- > Lung transplant surgery costs \$1M+ ²,
- > Post-hospitalization is expensive, life is at risk = surgeons are cautious
- Transplanting a lung relies on qualitative factors and assessment by the surgeon



References:

- (1) https://www.cihi.ca/en/access-data-and-reports
- (2) https://unos.org/data/transplant-trends/

TOR-dx[™] LUNG Panel Test

TOR-dx[™] Lung Panel detects inflammation at the molecular level to assess the health of the donor lung

- Enables Surgeons to Assess if Organ is Healthy for Transplant
- > Most donor lungs are discarded up to 80%*
- > TOR-dx[™] LUNG Panel clinical data has shown that up half of discarded lungs are viable
- > More viable donor lungs means more recipients lives are improved

Improving Success of Lung Transplants and Availability of Donor Lungs

*Source: JAMA Surg. 2019;154(12):1143-1150.doi:10.1001/jamasurg.2019.4079. Pub Online Oct. 9, 2019 Similar diagnostic test planned for both kidney and liver organs after TOR-dx[™] FDA approval.



"Integrating rapid diagnostics is a major step forward in lung transplantation. By providing transplant teams with quantitative metrics to more accurately assess donor lungs, we are moving decision making in transplantation into the era of personalized medicine."

- Dr. Shaf Keshavjee, Surgeon-in-Chief, Sprott Department of Surgery, Director, Toronto Lung Transplant Program and Director, Latner Thoracic Surgery Research Laboratories

TSX-V: SQD | OTCQB: SQIDF

SCI DIAGNOSTICS

TOR*dx*™: Technology Overview

- The TORdx[™] LUNG is a 4-plex cytokine assay for the measurement of four inflammatory markers (IL-1β, IL-6, IL-8 and IL-10) in lung perfusate fluid during *ex-vivo* lung perfusion ("EVLP")
- This 4-plex cytokine assay utilizes quantitative immunofluorescent technology to measure the concentration of circulating cytokines in the EVLP fluid over four-time points. This data is incorporated with other diagnostic results to generate the Toronto Lung Score (TLS)™, which is used by transplant physicians as part of the donor organ assessment process
- The *TORdx*[™] LUNG assay is used on the sqid**lite®** and sqid-**X®** systems and uses a perfusate fluid sample
- Application of real-time biomarker testing has long been desired to improve decision-making precision during EVLP and the TORdx[™] LUNG assay makes this a clinical reality
- The biomarker results of the donor lung while on EVLP predict the clinical outcomes of the recipient (≤3 days to extubation) with a 73% accuracy



RALI-D*x*[™] Severity/Triage Tests

Multi-use Test... Aids in Diagnosing Severity of COVID-19 Influenza or Other Adverse Respiratory Events

- > Triage tool aid doctors in treatment decisions send patient home or admit to hospital or to treat with advanced respiratory care measures
- > Advanced ICU monitoring tool
 - > 25 million ICU Patient days in US
 - > SQI expanding on a very positive pilot study with POC test
- > ~\$400 test that measures critical biomarkers predictive of severe "cytokine storm" and respiratory failure
- > Patients benefit from improved knowledge and ER staff have a cost-effect tool to discharge with improved confidence
- > Early assessment eases capacity at ER
- > Earlier assessment reduces morbidity, maximizes resources, reduces burden and costs on healthcare system

Current RALI-Dx (50-Minute Lab Test)



BENCH-TOP HOSPITAL LAB INSTRUMENT

Future RALI-fast & ICU (15-Minute POC

Test)



sqidlite® System

- SQI Diagnostics has developed the sqid family of instrument platforms to be used to analyze samples on their RALI-DxTM and TORdx[™] LUNG immunoassays
- The sqidlite[®] system is a multiplex immunoassay platform that automates the assay process for diluting and running samples, standards, controls, assay plate loading, incubating and washing for each individual sample.
- The sqidlite[®] system has been designed using industry-leading components from tier-1 suppliers such as Hamilton
- The sqidlite[®] system performs a fluorescent scan of each well in the microarray, analyzes the data, and generates a report containing results for all assay markers. The sqidlite[®] system also includes internal quality checks in the data analysis.



sqidlite[®] bench-top system



OWLSTONE Breath-Based Detection of Lung Infection / Transplant Rejection

- Partnership agreement between SQI and Owlstone Medical for the discovery, development and commercialization of breath-based biomarkers
- Extends SQI's markets to post-transplant, non-invasive monitoring of
 - Invasive Aspergillus (IA) lung infection
 - Lung Transplant Rejection
- Possible extension to other transplanted organs
- Convert standard of care from invasive transbronchial lavage (IA)
- and tissue collection (rejection) to breath sample
- Market is to regularly monitor all lung (& other organs) transplant patients for ~1 year





Precision Biomonitoring PCR Testing Acquisitioncl

SQI acquired all of the human testing business of Precision Biomonitoring Inc "PBI". This is a revenue and cash flow generating business selling COVID-19 PCR test kits and Point of Need testing devices.

Why Buy PBI: We are acquiring revenue, cash flow and molecular Dx technology platform

REVENUE and Positive Cash Flow GENERATING FROM DAY 1

- FY22 revenue of \$7.6M
- Nationwide Canada-Based PCR Testing Business
- Employee screening is focussed on Film/TV Production, Utilities, Mining, Hospitality & Manufacturing
- Exclusive distribution agreement with Biomeme for PCR testing and Franklin POC Testing systems
- Only Canadian distributor of QUIDEL Sofia2 Rapid Antigen test
- Non COVID products added in 2H22 for influenza and RSV

Leveraging Existing Customer Base to Cross Sell:

- New Biomeme Flu-COVID combined product once approved in Canada can be added to product line most requested addition by customers
- Triple Lock technology as lab-based, low cost Health Canada approved 96 well RT-PCR COVID19 opportunity

- Asset Purchase
- Price Paid: \$6.8mm
- Cash: 90%
- SQI Shares: 10%
- Closing on or before Feb 14, 2022

SQI's Acquired PCR Product Portfolio we are Buying

Type of Test		Covid RT-PCR Test	Lab-based COVID PCR Test			
Accuracy		Biomeme 96.99% Sensitivity	TripleLock 100% Sensitivity	Biomeme 96.99%	TripleLock 100%	
Product	Portable Thermocycler	Consur	nables	Sensitivity Sensitivity 96-well Microplates		
	(One-time, Capital	(Recurring (Consumables)			
	Equipment)	Portable Lab Based		Lab Based		
	Franklin three9	Go-Strips	TripleLock	Go-Plates	TripleLock	
		Go-Strips				
Product Owner	Biomeme (US)	Biomeme (US)	PBI / McMaster	Biomeme (US) Exclusive Distributorship	SQI	
Regulatory Status	HC Approved	HC Approved	HC Approved	HC Approved	HC Approved	
Date of Approval	2020-07-07	2020-07-07	2020-11-04	2020-07-07	2021-02-04	
Target Audience	Employers	Emple	oyers	Central La		



SQI distributing QUIDEL Sofia2 RAPID Antigen Test

The first Health Canada SARS COVID19 RAPID Antigen Test Approved for Asymptomatic Testing

- Makes this test ideal for employers, educators, governments screening of people with no COVID symptoms
- Performance close to lab-based PCR tests (96.7% accuracy*)
- 15-minute test preparation same as "take-home" antigen tests
- Gentle Nasal Swab the easy one
- Very inexpensive, mobile reader capable of single or batch testing

Sofia SARS Antigen FIA Clinical Performance*

	Reference Extracted RT-PCR assay					95% CI		
		POS	NEG	Total	PPA	96.7%	83.3%	99.4%
Sofia SARS Antigen FIA Assay	POS	29	0	29	NPA	100.0%	97.9%	100.0%
	NEG	1	179	180	PPV	100.0%	88.3%	100.0%
	Total	30	179	209	NPV	99.4%	96.9%	99.9%
					Prevalence	14.4%	7.4%	14.3%
					% agreement	99.5%		

*Please refer to the Package Insert for full study design and explanation.





Board of Directors



Why Invest...

- Our products address unmet needs with diagnostic tests that improve patients' lives
- Our addressable markets are known and very large
- We are transitioning our products to point of care to lower costs and accelerate adoption for our customers
- All commercial competencies in place and proven through development, regulatory and product launches
- SQI is at a commercial inflection point with much lower risk profile than "start-ups"
- SQI is a known and trusted partner

